Appropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study

Basit Öğe Kaydı
dc.authoridKaya, Caglar/0000-0002-2968-5352
dc.authoridMemic Sancar, Kadriye/0000-0003-1350-215X
dc.authorwosidTANIK, VEYSEL OZAN/AAC-6308-2020
dc.authorwosidKaya, Caglar/GSN-9700-2022
dc.authorwosidorscelik, özcan/A-6242-2016
dc.authorwosiddemirci, erkan/IVH-2862-2023
dc.authorwosidMemic Sancar, Kadriye/GVU-1673-2022
dc.contributor.authorDemirci, E.
dc.contributor.authorCelik, O.
dc.contributor.authorCil, C.
dc.contributor.authorTanik, V. O.
dc.contributor.authorSancar, K. Memic
dc.contributor.authorOrscelik, O.
dc.contributor.authorResulzade, M. M.
dc.date.accessioned2024-06-12T10:52:37Z
dc.date.available2024-06-12T10:52:37Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractOBJECTIVE: Aspirin is an essential drug in the prevention of atherosclerotic cardiovascular disease (ASCVD). It is ultimately indicated in a patient with ASCVD. However, its role is debated in primary prevention. We aimed to investigate the appropriateness of aspirin use in diabetic patients according to recommendations of recent guidelines. PATIENTS AND METHODS: ASSOS was a multicenter observational study investigating aspirin use in cardiology outpatient clinics. We evaluated aspirin use in diabetic patients in primary prevention from the ASSOS study. We also assessed the appropriate use of aspirin according to the European Society of Cardiology (ESC), American College of Cardiology/American Heart Association (ACC/AHA), American Diabetes Association (ADA), Consensus Statement of Endocrinology, Cardiology, and Nephrology (ENCARNE), and the United States Preventive Services Task Force (USPTF). RESULTS: A total of 5,007 patients of whom 1,537 had type 2 diabetes mellitus (DM) were included in the study. 1,132 of the total participants used aspirin for primary prevention; 313 of them had type 2 DM. Only 248 (76.7%), 132 (40.8%), and 128 (39.6%) diabetic patients indicated aspirin use according to the ESC/ INCARNE, ACC/AHA, and ADA/USPTF guidelines, respectively. CONCLUSIONS: Inappropriate aspirin use was common among diabetic patients, according to clinical practice guideline recommendations. In addition, the differences between the indications for the use of aspirin in diabetic patients according to the guidelines were remarkable. Guidelines that minimize these differences are needed for clinicians, and compliance with these guidelines in clinical practice could reduce inappropriate aspirin use.en_US
dc.identifier.endpage314en_US
dc.identifier.issn1128-3602
dc.identifier.issue1en_US
dc.identifier.pmid36647878en_US
dc.identifier.scopus2-s2.0-85146298549en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage307en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18777
dc.identifier.volume27en_US
dc.identifier.wosWOS:000921568000005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical And Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAspirinen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectGuidelinesen_US
dc.subjectPrimary Preventionen_US
dc.subjectAtherosclerotic Cardiovascular Diseasesen_US
dc.subjectAntiplatelet Therapyen_US
dc.subjectAtrial-Fibrillationen_US
dc.subjectRisk-Factorsen_US
dc.subjectScoreen_US
dc.subjectAssociationen_US
dc.subjectHemorrhageen_US
dc.subjectMellitusen_US
dc.titleAppropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu